TCRT Stock Overview
A clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Alaunos Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.85 |
| 52 Week High | US$13.30 |
| 52 Week Low | US$1.31 |
| Beta | -1.08 |
| 1 Month Change | -2.40% |
| 3 Month Change | 74.85% |
| 1 Year Change | -77.02% |
| 3 Year Change | -96.78% |
| 5 Year Change | -99.30% |
| Change since IPO | -99.42% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?
Nov 10
Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology
Oct 04Alaunos posts 51% tumor reduction for lung cancer therapy
Sep 21Alaunos sheds 52% ahead of data readout for T-cell therapy platform
Sep 15Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data
Aug 31Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02
Aug 15Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?
Jul 26Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?
Apr 06Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?
Dec 20Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?
May 11How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?
Mar 09We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely
Jan 15What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?
Nov 23
Shareholder Returns
| TCRT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.6% | -9.0% | -0.3% |
| 1Y | -77.0% | -15.0% | 8.1% |
Return vs Industry: TCRT underperformed the US Biotechs industry which returned -15.2% over the past year.
Return vs Market: TCRT underperformed the US Market which returned 8% over the past year.
Price Volatility
| TCRT volatility | |
|---|---|
| TCRT Average Weekly Movement | 26.5% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: TCRT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TCRT's weekly volatility has increased from 20% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 1 | Dale Hogue | www.alaunos.com |
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression.
Alaunos Therapeutics, Inc. Fundamentals Summary
| TCRT fundamental statistics | |
|---|---|
| Market cap | US$4.56m |
| Earnings (TTM) | -US$4.68m |
| Revenue (TTM) | US$10.00k |
456.4x
P/S Ratio-1.0x
P/E RatioIs TCRT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCRT income statement (TTM) | |
|---|---|
| Revenue | US$10.00k |
| Cost of Revenue | US$362.00k |
| Gross Profit | -US$352.00k |
| Other Expenses | US$4.33m |
| Earnings | -US$4.68m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.92 |
| Gross Margin | -3,520.00% |
| Net Profit Margin | -46,790.00% |
| Debt/Equity Ratio | 0% |
How did TCRT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 19:54 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alaunos Therapeutics, Inc. is covered by 22 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | BMO Capital Markets Equity Research |
| James Birchenough | BMO Capital Markets U.S. (Historical) |
| Vernon Bernardino | Brinson Patrick Securities Corporation |